Successful Robotic Brain Surgery In Panama Sets New Milestone In Neurovascular Treatments

XCath, a company focused on neuro-endovascular surgical robotics, and Crescent Enterprises, its largest shareholder, have announced the first successful human use of XCath's EVR robotic system.

This system was used to treat three patients with complex brain aneurysms. The procedures took place at The Panama Clinic in Panama City, led by Dr. Vitor Mendes Pereira and local investigator Dr. Anastasio Ameijeiras Sibauste.

The procedures mark only the second time a surgical robot has been used for intracranial neurovascular intervention. XCath's EVR is now the only endovascular robotic system in development that has achieved intracranial navigation or neurointerventional treatment. It is also the first triaxial neurovascular robot to perform such treatments.

Dr. Pereira highlighted the precision required for neurovascular interventions for brain aneurysms, which demand sub-millimetric accuracy and exceptional control. "With the success of these aneurysm procedures, XCath's system has demonstrated the potential to enhance human performance and bring a new level of precision to complex neurovascular cases," he said.

Brain aneurysms are a critical health concern affecting many people globally. Approximately 1 in 50 individuals have an unruptured brain aneurysm, often without symptoms until rupture occurs. Aneurysm ruptures cause around 500,000 deaths annually worldwide, with half of those affected being under age 50.

Stroke remains a leading cause of death and disability worldwide. Without treatment, patients lose about 2 million brain cells per minute. Tele-robotics can save crucial time by allowing specialists to reach patients quickly. Currently, only 2–3% of stroke patients globally have access to mechanical thrombectomy when needed.

The UAE has been pivotal in advancing medical technology solutions. In May 2024, during Abu Dhabi Global Healthcare Week (ADGHW), XCath demonstrated a simulated remote mechanical thrombectomy from Abu Dhabi on a simulated patient in South Korea.

"Unlocking clinical and commercial value in neurointervention starts with making life-saving intracranial care more replicable, more precise and more accessible when every minute counts," said Eduardo Fonseca, CEO of XCath. He emphasized that this milestone reflects the dedication of their team and lays a foundation for future advancements.

Dr. Fred Moll, Chairman of the XCath Board of Directors, expressed excitement over this achievement: "The successful completion of these procedures marks a significant milestone in the world of endovascular robotics as we seek to improve outcomes for patients impacted by aneurysms and strokes."

This historic milestone builds on significant momentum from the UAE in pioneering solutions in medical technology. Neeraj Agrawal from Crescent Enterprises noted that this progress highlights regional leadership in global healthcare innovation: "This milestone underscores how our value-focused investment strategy can deliver lifesaving impact."

The success of these procedures demonstrates how robotic assistance can standardize fine movements and decision execution. This technology can help transform less experienced physicians into consistent interventionists, improving outcomes and reducing complications.